Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! 2nd Global Bioequivalence Harmonisation Initiative – a great success Quality Management Systems in Early Phase Trials Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Immunogenicity DFI Non interventional Network Bioequivalence HTA Uveitis Database Early phase Dose linearity Pulse oximetry plethysmography Expert Sensitisation trials Charcoal Pituitary Copyright Phase I Unit Feasibility Post authorisation MCID Sequential designs Transdermal therapeutic system Steady state Anaesthesiologist Ophthalmologist Central surveillance system Adrenocortical Quality Assurance Lung Efficacy Drug Food Interaction Auditing Consultancy Pharmacology SOP based Glaucoma ADAM DUS Pilot study CDM IVIVC Gynaecological trials Authorities Inspection Audit US FDA Hormone replacement therapy Clinical trials Bioavailability SAS Design development MMM CRA CDSIC Intensive assessment station WinNonlin Clinical study Protocol COPD Ophthalmology Pharmacokinetics PAES Metered dose inhaler Quality Management System Eye disease Clinical Monitoring Phase IV Common cold Standardisation Asthma Local tolerability Xerostomia Statistical programming Protocol development Oncology Creativity Legal Information FDA Drug Drug Interaction Thuringia US CFR 21 Part 11 Rhine Main area Experience Hypothalamic IMPD Highly variable drugs Ovulation inhibition Slit lamp microscopy Patch adhesion Phase II Clinical pharmacology unit TTS HPA axis Phase IIa trials Quality Monitoring GLP Paediatricians Subcontractor qualification Dry powder inhaler GCP ANVISA CDISC IB Degeneration Life cycle management IEC Safety Training SDV Dry eye Ocular tolerability First in human Investigators brochure Oncologic network Data Validation Plan Elpro Statistical services OTC Patients Biopharmaceutics Allergy Clinical development program ICF Statistical Analysis Plan Product development Patch Source Data Verification Female adolescents Biopharmaceutical DDI Ophthalmological trials Healthy subjects Competence Absorption AGAH Sample size estimation Informed Consent Procedure Patient recruitment Axis FIM Inhalatives PASS Sore throat Data Management Plan Postmenopausal women Standard operating procedure Phase IIb trials Pharmacodynamic studies Biometrics SocraTec C&S Endpoint Scientific expertise Project Management NIS CRO Oncological patients Phase III Phase I MDI HRT Biosimilars Pragmatism In vitro in vivo correlation Spacious archive DPI CDASH Recruitment rates Children CRF Contraception Data management Edema Referral system Absorption windows EMA Cardiovascular surveillance Centralised procedure Macular Good Clinical Practice Legal representative GCP training Pharmacokintetics Dermal irritation Cough Scientific advice  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page